Migraine Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000
Buy Report View Sample

Published: September 30, 2022 Report Code: GDGMDHC22316IDB-ST

Select Item

Migraine is a disorder characterized by repeated attacks of severe headache. A migraine headache causes throbbing or pulsating pain, usually on only one side of the head. These headaches are often associated with nausea, vomiting, and extreme sensitivity to light and sound. Symptoms include problems speaking, tingling in face, arms, and shoulders, pain behind one of the eyes and pain that gets worse with routine physical activity.

The Migraine pipeline drugs market research report provides comprehensive information on the therapeutics under development for Migraine, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Migraine and features dormant and discontinued projects.

Migraine Pipeline Drugs Market Segmentation by Targets

Some of the targets of the Migraine pipeline drugs market are 5-Hydroxytryptamine Receptor 1D, 5-Hydroxytryptamine Receptor 1B, Calcitonin Gene Related Peptide, Calcitonin Gene Related Peptide Type 1 Receptor, Gamma-Aminobutyric Acid Type A Receptor Subunit, and 5-Hydroxytryptamine Receptor 2A.

Migraine Pipeline Drugs Market Analysis, by Targets

Migraine Pipeline Drugs Market Analysis, by Targets

For more Migraine pipeline drugs market target insights, download a free report sample

Migraine Pipeline Drugs Market Segmentation by Mechanism of Actions

Some of the mechanisms of action of the Migraine pipeline drugs market are 5-Hydroxytryptamine Receptor 1D Agonist, 5-Hydroxytryptamine Receptor 1B Agonist, Calcitonin Gene Related Peptide Inhibitor, Calcitonin Gene Related Peptide Type 1 Receptor Antagonist, 5-Hydroxytryptamine Receptor 2A Agonist, Pituitary Adenylate Cyclase Activating Polypeptide Inhibitor.

Migraine Pipeline Drugs Market Analysis, by Mechanism of Actions

Migraine Pipeline Drugs Market Analysis, by Mechanism of Actions

For more mechanism of action insights into the Migraine pipeline drugs market, download a free report sample

Migraine Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Migraine pipeline drugs market are oral, subcutaneous, intravenous, nasal, intramuscular, and transmucosal.

Migraine Pipeline Drugs Market Analysis, by Routes of Administration

Migraine Pipeline Drugs Market Analysis, by Routes of Administration

For more routes of administration insights into the Migraine pipeline drugs market, download a free report sample

Migraine Pipeline Drugs Market Segmentation by Molecule Types

The molecule types in the Migraine pipeline drugs market are Small Molecule, Monoclonal Antibody, Protein, Peptide, Recombinant Protein, and Synthetic Peptide.

Migraine Pipeline Drugs Market Analysis, by Molecule Types

Migraine Pipeline Drugs Market Analysis, by Molecule Types

For more molecule type insights into the Migraine pipeline drugs market, download a free report sample

Competitive Landscape

Some of the key companies in the Migraine pipeline drugs market are Klaria Pharma Holding AB, Biohaven Pharmaceutical Holding Company Ltd, Eli Lilly and Co, H. Lundbeck AS, Ceruvia Lifesciences LLC, and AbbVie Inc.

Migraine Pipeline Drugs Market Analysis, by Companies

Migraine Pipeline Drugs Market Analysis, by Companies

To know more about the Migraine pipeline drugs market companies, download a free report sample

Migraine Pipeline Drugs Market Report Overview

Key Targets 5-Hydroxytryptamine Receptor 1D, 5-Hydroxytryptamine Receptor 1B, Calcitonin Gene Related Peptide, Calcitonin Gene Related Peptide Type 1 Receptor, Gamma-Aminobutyric Acid Type A Receptor Subunit, and 5-Hydroxytryptamine Receptor 2A
Key Mechanism of Actions 5-Hydroxytryptamine Receptor 1D Agonist, 5-Hydroxytryptamine Receptor 1B Agonist, Calcitonin Gene Related Peptide Inhibitor, Calcitonin Gene Related Peptide Type 1 Receptor Antagonist, 5-Hydroxytryptamine Receptor 2A Agonist, Pituitary Adenylate Cyclase Activating Polypeptide Inhibitor
Key Routes of Administration Oral, Subcutaneous, Intravenous, Nasal, Intramuscular, and Transmucosal
Key Molecule Types Small Molecule, Monoclonal Antibody, Protein, Peptide, Recombinant Protein, and Synthetic Peptide
Key Companies Klaria Pharma Holding AB, Biohaven Pharmaceutical Holding Company Ltd, Eli Lilly and Co, H. Lundbeck AS, Ceruvia Lifesciences LLC, and AbbVie Inc.

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of migraine.
  • Reviews of pipeline therapeutics for Migraine by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • Reviews key companies involved in Migraine therapeutics and enlists all their major and minor projects.
  • Evaluation of Migraine therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Migraine.

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Migraine.

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding the Migraine pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

4P Therapeutics LLC
AbbVie Inc
Acadia Pharmaceuticals Inc
Achelios Therapeutics Inc
Acherx LLC
AEON Biopharma Inc
AgoneX Biopharmaceuticals Inc
Allodynic Therapeutics LLC
Amgen Inc
Amneal Pharmaceuticals Inc
AOBiome LLC
Arovella Therapeutics Ltd
Asarina Pharma AB
AstraZeneca Plc
Astrocyte Pharmaceuticals Inc
Avanir Pharmaceuticals Inc
Axsome Therapeutics Inc
Benuvia Therapeutics Inc
Better Life Pharmaceuticals Inc
Biogen Inc
Biohaven Pharmaceutical Holding Company Ltd
Cerecin Pte Ltd
Ceruvia Lifesciences LLC
Charleston Laboratories Inc
Citragen Pharmaceuticals Inc
Corium Inc
Crossject SA
Crystec Ltd
Curatis AG
DelNova Inc
Dr. Reddy's Laboratories Ltd
Eli Lilly and Co
Epalex Corp
Exxel Pharma Inc
Gubra ApS
H. Lundbeck AS
HEC Pharma Co Ltd
IACTA Pharmaceuticals Inc
InStar Technologies AS
IntelGenx Corp
Invisio Ltd
Ionis Pharmaceuticals Inc
Kallyope Inc
Kissei Pharmaceutical Co Ltd
Klaria Pharma Holding AB
Lateral Pharma Pty Ltd
MannKind Corp
Merck & Co Inc
Microgen
Mydecine Innovations Group Inc
NAL Pharmaceuticals Ltd
NeurAxon Pharma Inc
NutriBand Inc
OWP Pharmaceuticals Inc
Panaxia Pharmaceutical Industries Ltd
PassPort Technologies Inc (USA)
Pharmnovo AB
Pherin Pharmaceuticals Inc
Pulmatrix Inc
Qingdao Chia Tai Haier Pharmaceutical Co Ltd
RAFT Pharmaceuticals
Revance Therapeutics Inc
Saniona AB
Satsuma Pharmaceuticals Inc
Seurat Therapeutics Inc
Shandong Boan Biotechnology Co Ltd
Shanghai Junshi Bioscience Co Ltd
Sorrento Therapeutics Inc
Teva Pharmaceutical Industries Ltd
Tremeau Pharmaceuticals Inc
Trevena Inc
Trigemina Inc
TrioxBio Inc
Vaxxinity Inc
Xoc Pharmaceuticals Inc
Zosano Pharma Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Migraine – Overview

Migraine – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Migraine – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Migraine – Companies Involved in Therapeutics Development

Migraine – Drug Profiles

Migraine – Dormant Projects

Migraine – Discontinued Products

Migraine – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Migraine, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Target, 2022 (Contd..2)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2022 (Contd..2)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Migraine – Dormant Projects, 2022

Migraine – Dormant Projects, 2022 (Contd..1)

Migraine – Dormant Projects, 2022 (Contd..2)

Migraine – Dormant Projects, 2022 (Contd..3)

Migraine – Dormant Projects, 2022 (Contd..4)

Migraine – Dormant Projects, 2022 (Contd..5)

Migraine – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Migraine, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Migraine Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Migraine Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Central Nervous System reports
Pharmaceuticals
New
New Drug Approvals and Their Contract Manufacture - 2024 Edition
$4,995 | April 2024
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Migraine Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Migraine Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more